Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWolf Minerals Regulatory News (WLFE)

  • There is currently no data for WLFE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding - Award of Performance

28 Nov 2014 07:00

RNS Number : 2310Y
Wolf Minerals Limited
28 November 2014
 



In addition to the information contained in this Appendix 3B, the Company makes the following disclosures as required by the AIM Rules. On 28 November 2014, Mr Russell Clark was issued 1,318,293 Performance Rights. Following this issue, Mr Clark's holding in the Company is 83,333 ordinary shares, representing 0.010% of the outstanding issued share capital of the Company and 1,318,293 Performance Rights.

 

 

 

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

 

New issue announcement,

application for quotation of additional securities

and agreement

 

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

 

 

Name of entity

WOLF MINERALS LIMITED

 

ABN

11 121 831 472

 

We (the entity) give ASX the following information.

 

 

Part 1 ‑ All issues

You must complete the relevant sections (attach sheets if there is not enough space).

 

1

+Class of +securities issued or to be issued

 

(i) Performance Rights

 

(ii) Performance Rights

 

 

 

 

2

Number of +securities issued or to be issued (if known) or maximum number which may be issued

 

(i) 1,461,429 performance rights

 

(ii) 1,491,989 performance rights

 

 

 

 

3

Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

(i) The performance rights are issued in accordance with the Wolf Minerals Limited Performance Rights Plan, as re-adopted by shareholders on 21 November 2014. The vesting date is 30 June 2016. Upon vesting, one performance right is converted into one fully paid ordinary share in the Company for nil cash consideration. Vesting is subject to the following conditions:

 

a) 50% of performance rights will vest based on the Company's relative share price performance versus the AIM Basic Resources Index in accordance with a defined scale; and

b) 50% of performance rights will vest based upon the Company's Total Shareholder Return (TSR) performance as measured from 1 July 2014 to the vesting date of 30 June 2016.

 

(ii) The performance rights are issued in accordance with the Wolf Minerals Limited Performance Rights Plan, as re-adopted by shareholders on 21 November 2014. The vesting date is 30 June 2017. Upon vesting, one performance right is converted into one fully paid ordinary share in the Company for nil cash consideration. Vesting is subject to the following conditions:

 

a) 50% of performance rights will vest based on the Company's relative share price performance versus the AIM Basic Resources Index in accordance with a defined scale; and

b) 50% of performance rights will vest based upon the Company's Total Shareholder Return (TSR) performance as measured from 1 July 2014 to the vesting date of 30 June 2017.

 

 

 

 

 

4

Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

 

If the additional +securities do not rank equally, please state:

· the date from which they do

· the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

· the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

(i) No (not until vesting). Prior to vesting the performance rights do not carry a right to vote, receive dividends or generally participate in other corporate actions. However ordinary shares allocated upon vesting of the performance rights will rank equally with all existing fully paid ordinary shares on issue.

 

(ii) No (not until vesting). Prior to vesting the performance rights do not carry a right to vote, receive dividends or generally participate in other corporate actions. However ordinary shares allocated upon vesting of the performance rights will rank equally with all existing fully paid ordinary shares on issue.

 

 

 

 

5

Issue price or consideration

 

(i) Nil

 

(ii) Nil

 

 

 

 

6

Purpose of the issue

(If issued as consideration for the acquisition of assets, clearly identify those assets)

 

 

 

 

 

 

(i) & (ii)

 

The performance rights have been issued to the Managing Director, Mr Russell Clark, and other senior executives under the Wolf Minerals Limited Performance Rights Plan to provide an appropriate remuneration strategy and incentive for the Managing Director and senior executives to achieve the prescribed performance milestones set by the Board.

 

 

 

 

 

6a

Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

 

If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

Yes

 

 

 

 

6b

The date the security holder resolution under rule 7.1A was passed

21 November 2014

 

 

 

 

6c

Number of +securities issued without security holder approval under rule 7.1

Nil

 

 

 

 

6d

Number of +securities issued with security holder approval under rule 7.1A

Nil

 

 

 

 

6e

Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

 

Nil

 

 

 

 

6f

Number of +securities issued under an exception in rule 7.2

2,953,418 performance rights

 

 

 

 

6g

If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.

N/A

 

 

 

 

6h

If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

N/A

 

 

 

 

6i

Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements

201,033,903

 

 

 

7

+Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

28 November 2014

 

 

 

 

 

 

 

 

 

 

 

Number

+Class

8

Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)

 

807,845,616

Fully paid ordinary shares

 

 

Number

+Class

9

Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

 

 

 

478,012

 

 

 

100,418

 

 

 

524,086

 

 

 

223,882

 

 

 

529,845

 

 

 

226,342

 

 

 

529,845

 

 

 

226,342

 

 

 

172,776

 

 

 

73,807

 

 

 

 

3,200,000

 

 

 

1,461,429

 

 

1,491,989

 

 

366,945

 

Unlisted options exercisable at $0.333 on or before 1 April 2015.

 

Unlisted options exercisable at $0.3898 on or before 1 April 2015.

 

Unlisted options exercisable at $0.333 on or before 19 July 2015.

 

Unlisted options exercisable at $0.3898 on or before 19 July 2015.

 

Unlisted options exercisable at $0.333 on or before 16 October 2015.

 

Unlisted options exercisable at $0.3898 on or before 16 October 2015.

 

Unlisted options exercisable at $0.333 on or before 19 January 2016.

 

Unlisted options exercisable at $0.3898 on or before 19 January 2016.

 

Unlisted options exercisable at $0.333 on or before 30 January 2016.

 

Unlisted options exercisable at $0.3898 on or before 30 January 2016.

 

 

Unlisted options exercisable at $0.264 on or before 22 May 2016.

 

Performance rights with a vesting date of 30 June 2016.

 

Performance rights with a vesting date of 30 June 2017.

 

Performance rights with an expiry of 22 December 2020.

 

10

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

n/a

 

 

Part 2 ‑ Pro rata issue

 

11

Is security holder approval required?

 

 

 

12

Is the issue renounceable or non-renounceable?

 

 

13

Ratio in which the +securities will be offered

 

 

14

+Class of +securities to which the offer relates

 

 

15

+Record date to determine entitlements

 

 

 

16

Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

 

 

17

Policy for deciding entitlements in relation to fractions

 

 

 

18

Names of countries in which the entity has security holders who will not be sent new offer documents

Note: Security holders must be told how their entitlements are to be dealt with.

Cross reference: rule 7.7.

 

 

19

Closing date for receipt of acceptances or renunciations

 

 

 

 

 

 

20

Names of any underwriters

 

 

 

 

21

Amount of any underwriting fee or commission

 

 

22

Names of any brokers to the issue

 

 

 

 

23

Fee or commission payable to the broker to the issue

 

 

24

Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders

 

 

25

If the issue is contingent on security holders' approval, the date of the meeting

 

 

26

Date entitlement and acceptance form and offer documents will be sent to persons entitled

 

 

27

If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders

 

 

28

Date rights trading will begin (if applicable)

 

 

29

Date rights trading will end (if applicable)

 

 

 

 

30

How do security holders sell their entitlements in full through a broker?

 

 

31

How do security holders sell part of their entitlements through a broker and accept for the balance?

 

 

32

How do security holders dispose of their entitlements (except by sale through a broker)?

 

 

33

+Issue date

 

 

 

 

Part 3 ‑ Quotation of securities

You need only complete this section if you are applying for quotation of securities

 

34

Type of +securities

(tick one)

 

(a)

+Securities described in Part 1

 

(b)

All other +securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

 

Entities that have ticked box 34(a)

 Additional securities forming a new class of securities

 

 

Tick to indicate you are providing the information or documents

 

35

If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

 

 

36

If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories

1 - 1,000

1,001 - 5,000

5,001 - 10,000

10,001 - 100,000

100,001 and over

 

 

37

A copy of any trust deed for the additional +securities

 

Entities that have ticked box 34(b)

 

38

Number of +securities for which +quotation is sought

 

 

 

 

 

39

+Class of +securities for which quotation is sought

 

 

 

 

 

40

Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

 

If the additional +securities do not rank equally, please state:

· the date from which they do

· the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

· the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

 

 

 

 

41

Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

 

(if issued upon conversion of another +security, clearly identify that other +security)

 

 

 

 

 

Number

+Class

42

Number and +class of all +securities quoted on ASX (including the +securities in clause 38)

 

 

 

 

 

 

 

Quotation agreement

 

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

 

2 We warrant the following to ASX.

 

· The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.

 

· There is no reason why those +securities should not be granted +quotation.

 

· An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

 

· Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.

 

· If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

 

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

 

4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

 

 

 

 

Sign here: Pauline Carr Date: 28/11/2014

Joint Company secretary

 

 

 

== == == == ==

 

Appendix 3B - Annexure 1

 

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

 

Part 1

 

Rule 7.1 - Issues exceeding 15% of capital

Step 1: Calculate "A", the base figure from which the placement capacity is calculated

Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue

198,017,660

Add the following:

• Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2

• Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval

• Number of partly paid +ordinary securities that became fully paid in that 12 month period

Note:

• Include only ordinary securities here - other classes of equity securities cannot be added

• Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed

• It may be useful to set out issues of securities on different dates as separate line items

 

147,000

 

608,938,956

 

Nil

Subtract the number of fully paid +ordinary securities cancelled during that 12 month period

Nil

"A"

807,103,616

 

Step 2: Calculate 15% of "A"

"B"

0.15

[Note: this value cannot be changed]

Multiply "A" by 0.15

121,065,542

Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used

Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued:

• Under an exception in rule 7.2

• Under rule 7.1A

• With security holder approval under rule 7.1 or rule 7.4

Note:

• This applies to equity securities, unless specifically excluded - not just ordinary securities

• Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed

• It may be useful to set out issues of securities on different dates as separate line items

742,000

"C"

742,000

Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1

"A" x 0.15

Note: number must be same as shown in Step 2

121,065,542

Subtract "C"

Note: number must be same as shown in Step 3

742,000

Total ["A" x 0.15] - "C"

120,323,542

Note: this is the remaining placement capacity under rule 7.1

 

Part 2

 

Rule 7.1A - Additional placement capacity for eligible entities

Step 1: Calculate "A", the base figure from which the placement capacity is calculated

"A"

Note: number must be same as shown in Step 1 of Part 1

807,103,616

Step 2: Calculate 10% of "A"

"D"

0.10

Note: this value cannot be changed

Multiply "A" by 0.10

80,710,361

Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used

Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A

Notes:

• This applies to equity securities - not just ordinary securities

• Include here - if applicable - the securities the subject of the Appendix 3B to which this form is annexed

• Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained

• It may be useful to set out issues of securities on different dates as separate line items

Nil

"E"

Nil

 

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A

"A" x 0.10

Note: number must be same as shown in Step 2

80,710,361

Subtract "E"

Note: number must be same as shown in Step 3

Nil

Total ["A" x 0.10] - "E"

80,710,361

Note: this is the remaining placement capacity under rule 7.1A

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBLBDBRGDBGSR
Date   Source Headline
16th Oct 20185:30 pmRNSWolf Minerals
16th Oct 20189:05 amRNSResignation of Nomad and Broker
10th Oct 201812:46 pmRNSFunding Position Update
10th Oct 201811:25 amRNSSuspension - Wolf Minerals Limited
9th Oct 20188:07 amRNSFunding Position Update
27th Sep 20187:00 amRNSFunding Update and Voluntary ASX Suspension
20th Aug 20187:00 amRNSFunding Update
14th Aug 20187:00 amRNSFunding Update
30th Jul 20187:00 amRNSLifting of ASX Trading Halt
30th Jul 20187:00 amRNSSenior Debt Deferral and Additional Funding
26th Jul 20187:00 amRNSASX Trading Halt
18th Jul 20187:49 amRNSAppendix 5B
18th Jul 20187:44 amRNSQuarterly Activities Report
4th Jul 20187:00 amRNSappendix 3B
4th Jul 20187:00 amRNSDirector/PDMR Shareholding
4th Jul 20187:00 amRNSIssue of Equity
4th Jul 20187:00 amRNSAppendix 3Y
4th Jul 20187:00 amRNSCleansing Notice Letter
29th Jun 20187:58 amRNSDirector/PDMR Shareholding
29th Jun 20187:58 amRNSDirector/PDMR Shareholding
29th Jun 20187:58 amRNSDirector/PDMR Shareholding
29th Jun 20187:57 amRNSDirector/PDMR Shareholding
29th Jun 20187:57 amRNSIssue of Equity
29th Jun 20187:57 amRNSAppendix 3Y
29th Jun 20187:56 amRNSAppendix 3Y
29th Jun 20187:56 amRNSAppendix 3Y
29th Jun 20187:56 amRNSAppendix 3Y
29th Jun 20187:56 amRNSAppendix 3B
29th Jun 20187:56 amRNSCleansing Notice Letter
30th Apr 20187:00 amRNSAppendix 5B
30th Apr 20187:00 amRNSQuarterly Activities Report
20th Apr 20187:51 amRNSSettlement Agreement
29th Mar 201811:52 amRNSDIRECTOR SHAREHOLDING
29th Mar 201811:50 amRNSDIRECTOR SHAREHOLDING
29th Mar 201811:49 amRNSDIRECTOR SHAREHOLDING
29th Mar 201811:48 amRNSIssue of Equity and Change of Directors' Interests
29th Mar 201811:48 amRNSDIRECTOR SHAREHOLDING
29th Mar 201811:46 amRNSAppendix 3Y
29th Mar 201811:43 amRNSAppendix 3Y
29th Mar 201811:43 amRNSAppendix 3Y
29th Mar 201811:42 amRNSAppendix 3Y
29th Mar 201811:41 amRNSAppendix 3B
29th Mar 201811:39 amRNSCleansing Notice Letter
23rd Mar 20188:54 amRNSPublication of Updated Investor Presentation
21st Mar 20183:45 pmRNSAppointment of Managing Director
9th Mar 20182:00 pmRNSPrice Monitoring Extension
7th Mar 20187:00 amRNSInterim Financial Statements
1st Mar 20187:00 amRNSListing Rule Waiver
1st Mar 20187:00 amRNSDebt Restructure and Additional Funding
26th Feb 20187:00 amRNSChange of Registered Office

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.